Teva is committed to improving health and making people feel better. We invite you to join with us.

Building a next generation pharmaceutical company requires partners and new technologies, ideas, medicines, and insights. These can come from anywhere in the world. If you have innovations or ideas that will help transform our industry we want to hear from you. The following will help guide you on how to have your voice heard at Teva.

    This Webpage has the following sections:

    1. Teva’s General Criteria for Specialty Medicines

    2. Drug Modalities of interest

    3. Current Technology And Therapeutic Areas Of Interest

      •  Late-Stage opportunities
      • Central Nervous System (CNS)
        1. Neurodegenerative Diseases and Movement Disorders
        2. Pain
        3. Migraine/Headache
        4. Neuropsychiatry
      • Respiratory Diseases
        1. Asthma
        2. COPD
        3. Cystic Fibrosis
      • Oncology
      • Women’s Health
      • New Therapeutic Entities (NTEs)
      • Biosimilars
      • Diagnostics
      • Technologies

    4. Growth Market Opportunities
    5. Over the Counter Opportunities
    6. How to Contact Us

     

    TEVA’S GENERAL CRITERIA FOR SPECIALTY MEDICINES:

    We evaluate opportunities using the following criteria:

    1. Addresses significant unmet medical need

      • Unequivocally meets unmet needs anticipated at the time the opportunity makes it to the market
      • Not only addresses the needs of patients and their families, but also those of healthcare professionals and payers
    2. Supports Teva’s Personalized Medicine initiatives to deliver the right therapy to the right patients at the correct dose.
    3.  Technologies that improve on patient compliance and adherence approaches
      • E.g. eHealth/mHealth solutions, patient connectivity technologies, etc.
    4. Complementary and/or supportive to the Teva pipeline and our current therapeutic areas of interest as set out in the section below
    5. Synergistic with Teva’s capabilities

    DRUG MODALITIES OF INTEREST:

    • Teva is interested in a broad array of approaches:
      • Small molecule drugs
      • Biologic opportunities (peptides, proteins, antibodies, nucleic acids, etc.)
      • Biosimilar opportunities
      • Reformulation or delivery opportunities that offer clinically meaningful benefits and potential for expedited regulatory review

    CURRENT TECHNOLOGY AND THERAPEUTIC AREAS OF INTEREST INCLUDE:

    A. Late-stage Opportunities
    Teva is willing to entertain on- or near- market opportunities that complement our commercial presence across all therapeutic areas and across all our commercial regions. Please feel free to contact us should you have a late-stage opportunity

    B. Central Nervous System (CNS)

    • Neurodegenerative Diseases and Movement Disorders
      Teva aims at addressing the substantial unmet need of neurodegenerative diseases and movement disorders as evidenced in part by the acquisition of Auspex in 2015 and its lead program SD-809 potentially for the treatment of chorea associated with Huntington disease At the same time, we desire to limit the risk of failure in the clinic by focusing on well characterized disorders with disease progression biomarkers where feasible.
      • Treatment areas include:
        • Multiple Sclerosis:
          • Therapies targeting neuroprotection, remyelination, andregeneration pathways
          • Treatments for disease symptoms (such as fatigue, spasticity, cognition), and other approaches to holistically address the patient’s needs
          • Teva is not interested in general anti-inflammatory mechanisms, undifferentiated S1P agents, fumarates, injectable immune-modulators, or estrogenic therapies for MS.
        • Parkinson’s disease
        • Huntington's disease
        • Other, e.g. orphan neurodegenerative diseases (such as neuromyelitis optica)
      • Stage of opportunity:
        • Discovery-stage disease modifying therapies with biomarkers to identify the responder population
        • IND ready, clinical stage, and marketed opportunities
    • Pain
      Teva is committed to being a world-leader in pain therapies as evidenced by our marketed pain portfolio and pipeline programs
      • Treatment areas
        • Chronic pain (neuropathic, nociceptive and visceral pain)
        • Breakthrough cancer pain
      • Stage of opportunity
        • All stages, discovery through market
        • Reformulated marketed drugs meeting the General Criteria above
      • Not interested in
        • Treatments for acute pain 
    • Migraine/Headache
      Teva is committed to being a world-leader in migraine and headache in part as demonstrated by our acquisitions of Nupathe and Labrys Biologics in 2014 and the partnership with Heptares in 2015
      • Treatment areas
        • Migraine, including migraine sub-types (e.g., menstrual migraine) and migraine-related syndromes
        • Trigeminal Autonomic Cephalalgias (e.g., Cluster Headache
        • Post-traumatic Headache
      • Stage of opportunity
        • All stages, discovery through market
        • Reformulated marketed drugs meeting the General Criteria above
    • Neuropsychiatry
      • New Therapeutic Entities (NTEs) and New Chemical Entities (NCEs) with clinical Proof Of Concept (POC) that:
        • Improve adherence
        • Provide improved long term treatment
        • Are effective on the negative symptoms of Schizophrenia
        • Treat cognitive impairment associated with Schizophrenia
        • Address treatment resistant depression / inadequate response

    C. Respiratory

    Our respiratory portfolio is both broad and deep, occupying a leading position in this therapeutic area. In 2015 we completed the acquisition of the CareTRx platform (Gecko Health Innovations) in support of building a suite of solutions for our patients and physicians

    •  Disease areas (both symptomatic and disease modifying)
      • Asthma
      • COPD
      • Cystic Fibrosis
    • Stage of opportunity
      • Novel targets that target unmet needs. Candidates with POC clinical data preferred
        • Novel targets for these indications should have statistically significant POC data in humans demonstrating both safety and efficacy
      • Partnerships with companies who have compounds for inhalation development where our technology and expertise in inhaled drug delivery could be leveraged
    • Technologies
      • Technologies that improve on patient adherence
      • Technologies that help physicians treat patients

    D. Oncology

    • Treatment areas
      • oHematologic malignancies
      • Solid tumor indications
      • Innovative approaches to supportive care, e.g., antiemesis, neutropenia, and other adverse effects related to chemotherapy
    • Stage of opportunity
      • Only on- or near- market opportunities that complement our commercial presence
    • Therapeutic modalities
      • Including small molecules, biologics, and biosimilars

    E. Women’s Health

    • Treatment areas
      • Post-menopausal Health
      • Contraception
      • Reproductive Health
      • Pregnancy
      • Endometriosis
      • Uterine Fibroids
      • Sexually transmitted Infections
    • Stage of opportunity
      • Only on- or near- market opportunities that do not require R&D investment and that complement our commercial presence

    F. New Therapeutic Entities (NTEs)
    Teva’s R&D strategy builds on strong internal research and external innovation. Our NTE program is aimed at identifying and developing new specialty medicines that provide genuine advances on existing therapies by formulating, delivering, or using them in a unique way. Currently the NTE program has several R&D products in its pipeline in multiple therapeutic areas. The NTE pipeline features potential breakthrough therapies that will help transform patient care and sustain future growth. To learn more about NTEs please click here >

    Successful NTE partnering opportunities have the following attributes:

    • Differentiated products with demonstrable ability to meet clinical unmet needs
    • Expedited regulatory pathway with reduced development costs
    • Clear value to patients, healthcare practitioners, and payers

    G. Biosimilars
    Teva understands the potential biosimilars have as a growth driver to our long term strategy. We currently have 3 marketed biosimilar products Eporatio (epoetin theta), Ovaleap® (follitropin alfa) and Tevagrastim (filgrastim) and will be an active player in biosimilars. Successful biosimilar opportunities would have the following attributes:

    • Short time to market
    • High level of CMC execution supported by pre-clinical packages that clearly prove biosimilarity in the context of guidelines established by worldwide regulatory agencies
    • Possible consideration of earlier stage R&D collaborative efforts on wave 3 biosimilar products

    H. Diagnostics
    Teva is interested in technologies that support our therapeutic areas from diagnosis to disease monitoring,. All development stages of diagnostics are relevant. Primary interest is focused on:

    • Point of care diagnostics
      • Designed for in-office use by healthcare professionals
    • In-home diagnostics
      • Designed for use by patients in the home setting
    • Mobile/App-based diagnostics
      • Designed for use by patients, caregivers, and healthcare professionals alike

    I. Technologies and Patient Solutions
    Teva is very interested in cutting edge technologies. We recently announced deals with Microchips  and the acquisition of the CareTRx (Gecko Health Innovations) platform

    • eHealth/mHealth technologies
    • Patient connectivity technologies and devices
      • Wearable /on body injectors
      • Implantable devices
      • Bio-Feedback
    • Smart-packaging solutions
    • 3-D Printing
    • Delivery technologies, including
      • Drug-device combinations
      • Formulations
      • Innovation in needle technologies
      • Transdermal technologies
      • Microneedle technologies
      • Gastro-retention technologies

     

    European and Growth Market Opportunities

    European Markets

    For the European markets we are looking for products to market and distribute which leverage our existing speciality portfolio and commercial platforms.
    We are mainly looking for products in pre-registration or at commercial stages – however are also willing to assist a partner to get a late-stage drug approved in Europe and to help build a value-proposition for its pricing, reimbursement and market access.
    We prefer a region-wide deal, but are also well skilled and familiar with country-by-country distribution, co-marketing or co-promotion arrangements.
    We offer broad commercial coverage, excellent relationships with regulators and pricing agencies, and can communicate the value proposition of what the product brings to the patients.

    Growth Markets:

    The Teva Growth Markets region includes all ex US/EU countries. Teva has a leading position, established presence and strong sales, marketing & regulatory capabilities, in key growth markets including Japan, Russia (+CIS), Turkey, Israel, Australia (+NZ) South Korea, and LATAM (Brazil, Mexico, Argentina, Chile, Peru and Venezuela).
    For these markets and others we are looking for new products to market and distribute, to leverage on our strong regulatory and commercial platforms. We are looking for commercial products, as well as products in advanced development (Phase III and pre-registration stages)
    Teva can offer dedicated, experienced, multinational & local leading partnerships in multiple territories.

    Over the Counter

    OTC’s
    Since 2011, Teva's OTC business has been integrated with the OTC business of the Procter & Gamble Company, under our global (excluding N. America) joint venture - PGT Healthcare. PGT Healthcare consolidates, manages and is focused on growing all Teva and P&G OTC and Vitamins, Minerals and Supplements (VMS) businesses, outside of North America.

    PGT Healthcare’s portfolio includes Vicks — the world’s #1 selling cough & cold brand, Ratiopharm — the #1 OTC brand in Germany, and other leading brands like Vibovit, Ambrobene, Hylak, Novo-Passit, and Gastal.
    We have more than 160 brands, sold in more than 65 countries


    We offer:
    Exceptional partnering opportunities, with a portfolio of leading brands, supported by best-in-class consumer understanding, brand-building and advertising scale, as well as global capabilities in product development, registration and manufacturing.

    We also offer go-to-market scale across all retail channels, with a wide geographical footprint.

    We are interested in:
    Worldwide opportunities in licensing-in of developments and transfer of available registration dossiers (EU CTD and other registrable formats) for Over the Counter
    (OTC), Food Supplements and Medical Devices categories.
    Preference is given to the therapy areas of Cough & Cold, VMS (Vitamins, Minerals and Supplement), Digestive Health, Probiotics, Gastroenterology, and Pain Management.
    Early launch opportunities in emerging markets, especially LATAM and Asia
    New and novel technologies, delivery platforms, product presentations, dosage forms and packaging ideas.

     

     

    Contact Us

    Teva wants to hear from you!

    Our business development activities are led by pharmaceutical professionals with extensive experience in managing discussions, structuring deals and executing agreements.

    Please feel free to send us your opportunities through the email below. We make it our business to provide timely feedback.

    Eileen.kerper@tevapharm.com